Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein... Editorial 2105 SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Conflict of interest: none declared. . . Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U, CULPRIT-SHOCK Investigators. PCI strategies in patients with acute References . myocardial infarction and cardiogenic shock. N Engl J Med 2017;377:2419–2432. 1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio . 6. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LSD, van Domburg RT, ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Serruys PW. Percutaneous left ventricular assist devices vs. intra-aortic balloon Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, ESC pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of Scientific Document Group. 2017 ESC Guidelines for the management of acute controlled trials. Eur Heart J 2009;30:2102–2108. myocardial infarction in patients presenting with ST-segment elevation: The Task 7. Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in car- Force for the management of acute myocardial infarction in patients presenting . diogenic shock. Eur Heart J 2014;35:156–167. with ST-segment elevation of the European Society of Cardiology (ESC). Eur . 8. Kapur NK, Qiao X, Paruchuri V, Morine KJ, Syed W, Dow S, Shah N, Pandian N, Heart J 2018;39:119–177. Karas RH. Mechanical pre-conditioning with acute circulatory support before 2. Diepen S van, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, reperfusion limits infarct size in acute myocardial infarction. JACC Heart Fail 2015; Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG, 3:873–882. American Heart Association Council on Clinical Cardiology; Council on 9. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes . outcomes. Circulation 2008;117:686–697. Research; and Mission: Lifeline. Contemporary management of cardiogenic . 10. Obling L, Frydland M, Hansen R, Møller-Helgestad OK, Lindholm MG, Holmvang shock: a scientific statement from the American Heart Association. Circulation L, Ravn HB, Wiberg S, Thomsen JH, Jensen LO, Kjærgaard J, Møller JE, Hassager 2017;136:e232–e268. C. Risk factors of late cardiogenic shock and mortality in ST-segment elevation 3. Po¨ss J, Ko¨ster J, Fuernau G, Eitel I, Waha S de, Ouarrak T, Lassus J, Harjola V-P, myocardial infarction patients. Eur Heart J Acute Cardiovasc Care 2018;7:7–15. Zeymer U, Thiele H, Desch S. Risk stratification for patients in cardiogenic shock . 11. Auffret V, Cottin Y, Leurent G, Gilard M, Beer JC, Zabalawi A, Chague´ F, Filippi after acute myocardial infarction. J Am Coll Cardiol 2017;69:1913–1920. . E, Brunet D, Hacot JP, Brunel P, Mejri M, Lorgis L, Rouault G, Druelles P, Cornily 4. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller JC, Didier R, Bot E, Boulanger B, Coudert I, Loirat A, Bedossa M, Boulmier D, CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revasculariza- . Maza M, Le Guellec M, Puri R, Zeller M, Le Breton H; On behalf of the ORBI tion in acute myocardial infarction complicated by cardiogenic shock. SHOCK . and RICO Working Groups. Predicting the development of in-hospital cardio- Investigators. Should We Emergently Revascularize Occluded Coronaries for genic shock in patients with ST-segment elevation myocardial infarction treated Cardiogenic Shock. N Engl J Med 1999;341:625–634. by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J 5. Thiele H, Akin I, Sandri M, Fuernau G, Waha S de, Meyer-Saraei R, Nordbeck P, . Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix . 2018;39:2090–2102. doi:10.1093/eurheartj/ehx648 Corrigendum Online publish-ahead-of-print 24 November 2017 ................................................................................................ .................................................................. Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 in- hibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017); doi:10.1093/ eurheartj/ehx549]. The authors of the above article wish to inform readers that the following correction has been made post-publication: figure 4 has been corrected to amend the text ‘refer to Box 3’ to ‘refer to text’. V C Published on behalf of the European Society of Cardiology. All rights reserved. The Author 2017. For permissions, please email: journals.permissions@oup.com. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

European Heart Journal , Volume 39 (22): 1 – Nov 24, 2017
Download PDF
1 page

Loading next page...
 
/lp/ou_press/corrigendum-to-2017-update-of-esc-eas-task-force-on-practical-clinical-Qelf89V0gg
Publisher
Oxford University Press
Copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
ISSN
0195-668X
eISSN
1522-9645
DOI
10.1093/eurheartj/ehx648
Publisher site
See Article on Publisher Site

Abstract

Editorial 2105 SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Conflict of interest: none declared. . . Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U, CULPRIT-SHOCK Investigators. PCI strategies in patients with acute References . myocardial infarction and cardiogenic shock. N Engl J Med 2017;377:2419–2432. 1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio . 6. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LSD, van Domburg RT, ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Serruys PW. Percutaneous left ventricular assist devices vs. intra-aortic balloon Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, ESC pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of Scientific Document Group. 2017 ESC Guidelines for the management of acute controlled trials. Eur Heart J 2009;30:2102–2108. myocardial infarction in patients presenting with ST-segment elevation: The Task 7. Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in car- Force for the management of acute myocardial infarction in patients presenting . diogenic shock. Eur Heart J 2014;35:156–167. with ST-segment elevation of the European Society of Cardiology (ESC). Eur . 8. Kapur NK, Qiao X, Paruchuri V, Morine KJ, Syed W, Dow S, Shah N, Pandian N, Heart J 2018;39:119–177. Karas RH. Mechanical pre-conditioning with acute circulatory support before 2. Diepen S van, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, reperfusion limits infarct size in acute myocardial infarction. JACC Heart Fail 2015; Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG, 3:873–882. American Heart Association Council on Clinical Cardiology; Council on 9. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes . outcomes. Circulation 2008;117:686–697. Research; and Mission: Lifeline. Contemporary management of cardiogenic . 10. Obling L, Frydland M, Hansen R, Møller-Helgestad OK, Lindholm MG, Holmvang shock: a scientific statement from the American Heart Association. Circulation L, Ravn HB, Wiberg S, Thomsen JH, Jensen LO, Kjærgaard J, Møller JE, Hassager 2017;136:e232–e268. C. Risk factors of late cardiogenic shock and mortality in ST-segment elevation 3. Po¨ss J, Ko¨ster J, Fuernau G, Eitel I, Waha S de, Ouarrak T, Lassus J, Harjola V-P, myocardial infarction patients. Eur Heart J Acute Cardiovasc Care 2018;7:7–15. Zeymer U, Thiele H, Desch S. Risk stratification for patients in cardiogenic shock . 11. Auffret V, Cottin Y, Leurent G, Gilard M, Beer JC, Zabalawi A, Chague´ F, Filippi after acute myocardial infarction. J Am Coll Cardiol 2017;69:1913–1920. . E, Brunet D, Hacot JP, Brunel P, Mejri M, Lorgis L, Rouault G, Druelles P, Cornily 4. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller JC, Didier R, Bot E, Boulanger B, Coudert I, Loirat A, Bedossa M, Boulmier D, CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revasculariza- . Maza M, Le Guellec M, Puri R, Zeller M, Le Breton H; On behalf of the ORBI tion in acute myocardial infarction complicated by cardiogenic shock. SHOCK . and RICO Working Groups. Predicting the development of in-hospital cardio- Investigators. Should We Emergently Revascularize Occluded Coronaries for genic shock in patients with ST-segment elevation myocardial infarction treated Cardiogenic Shock. N Engl J Med 1999;341:625–634. by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J 5. Thiele H, Akin I, Sandri M, Fuernau G, Waha S de, Meyer-Saraei R, Nordbeck P, . Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix . 2018;39:2090–2102. doi:10.1093/eurheartj/ehx648 Corrigendum Online publish-ahead-of-print 24 November 2017 ................................................................................................ .................................................................. Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 in- hibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017); doi:10.1093/ eurheartj/ehx549]. The authors of the above article wish to inform readers that the following correction has been made post-publication: figure 4 has been corrected to amend the text ‘refer to Box 3’ to ‘refer to text’. V C Published on behalf of the European Society of Cardiology. All rights reserved. The Author 2017. For permissions, please email: journals.permissions@oup.com.

Journal

European Heart Journal – Oxford University Press

Published: Nov 24, 2017

There are no references for this article.